Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer

被引：0

作者：

N Takigawa

K Kiura

Y Segawa

Y Watanabe

H Kamei

T Moritaka

T Shibayama

H Ueoka

K Gemba

T Yonei

M Tabata

T Shinkai

S Hiraki

M Takemoto

S Kanazawa

K Matsuo

M Tanimoto

机构：

[1] Oncology,Department of Hematology

[2] and Respiratory Medicine,Department of Medicine and Thoracic Oncology

[3] Okayama University Graduate School of Medicine,Department of Internal Medicine

[4] Dentistry,Department of Internal Medicine

[5] and Pharmaceutical Sciences & Okayama University Hospital,Department of Pulmonary Medicine

[6] National Hospital Organization,Department of Pulmonary Medicine

[7] Shikoku Cancer Center,Department of Medicine

[8] Okayama Red Cross Hospital,Department of Pulmonary Medicine

[9] Sumitomo Besshi General Hospital,Department of Pulmonary Medicine

[10] Ehime Prefectural Central Hospital,Department of Radiology

[11] National Hospital Organization,Department of Epidemiology and Prevention

[12] Minami-Okayama Medical Center,undefined

[13] National Hospital Organization,undefined

[14] Sanyo Hospital,undefined

[15] Okayama Rosai Hospital,undefined

[16] Okayama Medical Center,undefined

[17] Okayama University Graduate School of Medicine,undefined

[18] Dentistry,undefined

[19] and Pharmaceutical Sciences & Okayama University Hospital,undefined

[20] Aichi Cancer Center Research Institute,undefined

来源：

British Journal of Cancer | 2006年 / 95卷

关键词：

non-small-cell lung cancer; chemotherapy; radiotherapy; second primary cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Long-term cancer survivors risk development of second primary cancers (SPC). Vigilant follow-up may be required. We report outcomes of 92 patients who underwent chemoradiation for unresectable stage III non-small-cell lung cancer, with a median follow-up of 8.9 years. The incidence of SPC was 2.4 per 100 patient-years (95% confidence interval: 1.0–4.9).

引用

页码：1142 / 1144

页数：2

共 92 条

[1]

Allan JM(2005)Mechanisms of therapy-related carcinogenesis Nat Rev Cancer 5 943-955

[2]

Travis LB(2006)Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients Ann Oncol 17 473-483

[3]

Aupérin A(2005)Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection? Lung Cancer 49 109-115

[4]

Le Pechoux C(2005)Second primary tumors involving non-small cell lung cancer: prevalence and its influence on survival Chest 127 1152-1158

[5]

Pignon JP(2005)Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group J Clin Oncol 23 2955-2961

[6]

Koning C(1995)Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group Ann Thorac Surg 60 615-622

[7]

Jeremic B(2001)Second cancers occurring in patients with early stage non-small-cell lung cancer treated with chest radiation therapy alone J Clin Oncol 19 1056-1063

[8]

Clamon G(2006)Second primary cancers in patients with stage III non-small cell lung cancer successfully treated with chemo-radiotherapy Jpn J Clin Oncol 36 7-11

[9]

Einhorn L(2003)Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer Br J Cancer 89 795-802

[10]

Ball D(1995)Incidence of local recurrence and second primary tumors in resected stage I lung cancer J Thorac Cardiovasc Surg 109 120-129

← 1 2 3 4 5 6 7 8 9 10 →